[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556414":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":27,"locations":32,"responsibleParty":44,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"immunocompetent",null,"immunocompetent patients with digestive symptoms (n=150)",[13],"Other: bacteriophage detection",{"label":15,"type":10,"description":16,"interventionNames":17},"immunocompromised","immunocompromised patients with digestive symptoms (n=150)",[13],[19],{"type":6,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"bacteriophage detection",[9,15],[23],{"name":24,"affiliation":25,"role":26},"Cédric Hartard","CHRU Nancy","PRINCIPAL_INVESTIGATOR",[28],{"name":24,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","0383153046","c.hartard@chru-nancy.fr",[33],{"facility":25,"status":10,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":10},"Nancy","54000","France","FR",{"type":39,"coordinates":40},"Point",[41,42],6.18496,48.68439,{"lat":42,"lon":41},{"type":26,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"HARTARD Cédric","Principal Investigator","100556414","prevalence-of-faecal-bacteriophage-in-patients-with-digestive-symptoms-100556414",false,"NCT06524791","Prevalence of Faecal Bacteriophage in Patients With Digestive Symptoms","Evaluation of the Prevalence of Faecal Bacteriophage Carriage in Patients With Digestive Symptoms.","PREPHAGE","Inclusion Criteria:\n\n* Age between 18 and 60.\n* Persons having developed gastrointestinal symptoms justifying microbiological stool testing at the time of hospitalization.\n* Person having received full information on the organization of the research and not having objected to the use of this data\n\nExclusion Criteria:\n\n* Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code.\n* Pregnant or breast-feeding women,\n* Minors (not emancipated),\n* Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice),\n* Persons of full age who are unable to give their consent.\n* Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1.","ALL","18 Years","60 Years",{"count":59,"type":60},300,"ESTIMATED","1 Day","OBSERVATIONAL","Define the prevalence of fecal phage carriage in individuals with digestive symptoms (i) Determine the concentrations of infectious fecal phages in the stools of individuals with digestive symptoms (detection by culture)\n\n(ii) Determine fecal phage genome concentrations in the stools of individuals with digestive symptoms (PCR detection)\n\n(iii) Explore factors that could impact fecal phage carriage (patients with digestive symptoms vs. healthy individuals, immunocompromised patients vs. immunocompetent patients)",[65],"Gastroenteritis",[67],"bacteriophages","NOT_YET_RECRUITING","2024-07-27",{"date":71,"type":72},"2024-07-30","ACTUAL",{"date":74,"type":60},"2024-11-15",{"date":76,"type":60},"2025-11-15",{"name":5,"class":6},1]